Bhavesh C Variya1, Anita K Bakrania1, Snehal S Patel2. 1. Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat 382481, India. 2. Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat 382481, India. Electronic address: snehal.patel@nirmauni.ac.in.
Abstract
BACKGROUND: Nature has gifted a variety of vital phytochemicals having potential therapeutic application against various ailments. Emblica officinalis (E. officinalis), an ancient plant, has long been used as a remedy for diabetes and cardiovascular complications, and presence of abundant amount of gallic acid could be accountable for its medicinal potential. PURPOSE: The study was aimed to determine the in-vivo and in-vitro anti-diabetic potential of gallic acid and fruit juice of E. officinalis. Molecular mechanism of gallic acid as well as fruit juice of E. officinalis for anti-diabetic potential has also been revealed. EXPERIMENTAL STUDY DESIGN: Anti-diabetic potential of E. officinalis and gallic acid was evaluated in 3T3-L1 preadipocytes and various animal models like db/db mice and fructose administered rats. PPAR-γ expression and glucose translocation were observed using western blot and PCR techniques. RESULTS: Treatment of E. officinalis fruit juice and gallic acid facilitated their glucose homeostasis; improved insulin sensitivity; reduced obesity; abridged elevated blood pressure and declined cholesterol level, and also induced adipogenesis in 3T3-L1 adipocytes. Mechanistically, treatment increased expression of PPAR-γ through activation of C/EBPs and simultaneously increased Glut4 translocation in 3T3-L1 adipocytes. Moreover, gallic acid treatment increased insulin sensitivity through activation of Akt rather than AMPK signaling pathway while fruit juice of E. officinalis showed dual activation, Akt and AMPK as well. CONCLUSION: These findings reveal the role of gallic acid in E. officinalis mediated antidiabetic potential, and delineate the upregulation of pAkt, PPAR-γ and Glut4 in gallic acid mediated antidiabetic activity, thus providing potential therapy for diabetes and related disorders.
BACKGROUND: Nature has gifted a variety of vital phytochemicals having potential therapeutic application against various ailments. Emblica officinalis (E. officinalis), an ancient plant, has long been used as a remedy for diabetes and cardiovascular complications, and presence of abundant amount of gallic acid could be accountable for its medicinal potential. PURPOSE: The study was aimed to determine the in-vivo and in-vitro anti-diabetic potential of gallic acid and fruit juice of E. officinalis. Molecular mechanism of gallic acid as well as fruit juice of E. officinalis for anti-diabetic potential has also been revealed. EXPERIMENTAL STUDY DESIGN: Anti-diabetic potential of E. officinalis and gallic acid was evaluated in 3T3-L1 preadipocytes and various animal models like db/db mice and fructose administered rats. PPAR-γ expression and glucose translocation were observed using western blot and PCR techniques. RESULTS: Treatment of E. officinalis fruit juice and gallic acid facilitated their glucose homeostasis; improved insulin sensitivity; reduced obesity; abridged elevated blood pressure and declined cholesterol level, and also induced adipogenesis in 3T3-L1 adipocytes. Mechanistically, treatment increased expression of PPAR-γ through activation of C/EBPs and simultaneously increased Glut4 translocation in 3T3-L1 adipocytes. Moreover, gallic acid treatment increased insulin sensitivity through activation of Akt rather than AMPK signaling pathway while fruit juice of E. officinalis showed dual activation, Akt and AMPK as well. CONCLUSION: These findings reveal the role of gallic acid in E. officinalis mediated antidiabetic potential, and delineate the upregulation of pAkt, PPAR-γ and Glut4 in gallic acid mediated antidiabetic activity, thus providing potential therapy for diabetes and related disorders.
Authors: Mater H Mahnashi; Yahya S Alqahtani; Bandar A Alyami; Ali O Alqarni; Sultan A Alqahl; Farhat Ullah; Abdul Sadiq; Alam Zeb; Mehreen Ghufran; Alexey Kuraev; Asif Nawaz; Muhammad Ayaz Journal: BMC Complement Med Ther Date: 2022-01-27
Authors: Gaber El-Saber Batiha; Oludare M Ogunyemi; Hazem M Shaheen; Funso R Kutu; Charles O Olaiya; Jean-Marc Sabatier; Michel De Waard Journal: Molecules Date: 2022-08-14 Impact factor: 4.927
Authors: Tajudeen O Obafemi; Kikelomo F Jaiyesimi; Adenike A Olomola; Oluwaseun R Olasehinde; Oyindamola A Olaoye; Funmilayo D Adewumi; Blessing A Afolabi; Olusola B Adewale; Christopher O Akintayo; Oluwafemi A Ojo Journal: Toxicol Rep Date: 2021-07-17